- Policy
- Goal of generic for Atozet is to be approved in next January
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- Chong Kun Dang's consignment-produced hyperlipidemia combination drug 'Atozet (Atorvastatin-Ezetimibe) is known to have applied for approval this month and is aiming for approval in next January. In that Atozet’s PMS by MDS will expire in next January, it is faster to acquire product approval than generics that have undergone bioequivalen
- Company
- Combination therapy of Mabthera is on the rise
- by Eo, Yun-Ho Sep 22, 2020 06:26am
- In the field of Chronic Lymphocytic Leukemia (CLL), a combination therapy of a new drug and 'Mabthera (Rituximab)' is attracting attention. According to related industries, the combination therapy of 'Imbruvica (Ibrutinib)' and Mabthera recently obtained approval in Europe after the US. The HIRA’s Pharmaceutical Benefits Advisory Committ
- Company
- Korean companies take drug patent strategy to next level
- by Kim, Jin-Gu Sep 22, 2020 06:26am
- The South Korean pharmaceutical companies are evolving their patent strategies. In the first half of the year, the companies set the historic record of registering the most number of patents. Apparently, their number of patents is on par with multinational pharmaceutical companies’. According to Ministry of Food and Drug Safety (MFDS) and K
- Company
- Sales in the outpatient prescription drug market are active
- by Chon, Seung-Hyun Sep 21, 2020 06:13am
- It has been shown that the outpatient prescription drug market has not been hit even with the recent spread of COVID-19) patients. Even though sales activities contracted due to level 2 social distancing, the total prescription drug volume recorded a growth trend last month. According to UBIST, a drug research institute on the 20th, the amoun
- Opinion
- [Reporter’s Note] Will KRPIA appoint a Korean chairman?
- by Eo, Yun-Ho Sep 21, 2020 06:12am
- While a few multinational pharmaceutical companies have confirmed their foreign executives would be leaving the position, the Korean Research-based Pharmaceutical Industry Association’s (KRPIA) board of director (BOD) is also expected to undergo some changes as well. The two foreign executives bidding farewell are MSD Korea’s CEO Avi B
- Policy
- Acromegaly and Huntington’s disease drugs win approval
- by Lee, Tak-Sun Sep 21, 2020 06:12am
- The South Korean health authority granted licenses for Pfizer Pharmaceutical Korea and Teva Handok, respectively. Pfizer’s acromegaly treatment and Teva Handok’s Huntington’s disease treatment would be now accessible to the patients in need of treatment. The Ministry of Food and Drug Safety (MFDS) granted approval on Somavert (pegvis
- Policy
- Cancer Fund Act is promoted
- by Lee, Jeong-Hwan Sep 21, 2020 06:12am
- A bill is being promoted to strengthen the guarantee of expensive anticancer drugs for cancer patients by establishing a cancer management fund. The goal is to improve the reality that patients are deprived of treatment opportunities due to delays in health insurance payments for innovative treatments such as immune anticancer drugs due t
- Policy
- Certican's drug prices will be cut from the 20th
- by Kim, Jung-Ju Sep 21, 2020 06:12am
- The aftermath of the dismissal of the patent lawsuit for Novartis Korea's immunosuppressant Certican (Everolimus) is also reflected in the lawsuit for insurance benefits between the government and companies. The drug price cuts, which the government tried to enforce last year, were suspended due to lawsuits, resumed after a year. The 7th
- Company
- Lilly's Olumiant, is clinically approved for COVID-19
- by Kim, Jin-Gu Sep 18, 2020 06:30am
- Eli Lilly's autoimmune disease treatment 'Olumiant (Baricitinib)' has begun phase III clinical trial targeting COVID-19 patients in Korea. It is the second clinical trial in Korea related to COVID-19 after Remdesivir by Gilead Science. On the 7th, the MFDS approved a phase III clinical trial plan of Baricitinib (LY3009104) in Lilly Korea f
- Opinion
- [Reporter’s Note] “Loonshots” in new drug development
- by An, Kyung-Jin Sep 18, 2020 06:30am
- I finally caught up to read the bestselling book, “Loonshots” that Bill Gates praised as ‘a book to carry around in your bag to read.’ The book is written by Safi Bahcall, who received a doctorate degree in physics from Stanford University and co-founded ‘Synta Pharmaceuticals.’ The author defines “Loonshots” as “a neglected proje
